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• Procalcitonin (PCT) is a highly sensitive and specific 
biomarker of inflammation and bacterial infections1. 
• Specific levels (e.g. PCT ≥ 0.25-0.50 ng/mL) can be 
used to guide antibiotic initiation and prompt antibiotic 
discontinuation in conjunction with clinical judgment1,2.
• PCT-driven antibiotic treatment has been shown to 
shorten antibiotic exposure by 2-3.5 days and reduce 
antibiotic usage by 30% in critically ill patients without 
increasing adverse clinical outcomes2-4.
• 3,531 PCT tests were performed at LVHN in 2018 –
accounting for $436,925.94 in charges.
• Some patients (n=41, 5.5%) received >2 PCT tests (range= 
3-6) during a single hospital admission.
• Patients with a negative (<0.25 ng/mL) first PCT result were 
more likely (23.0% vs 77.0%) to have non-PCT driven 
antibiotic initiation (Table 1). 
• For concordant follow-up PCT testing, antibiotic 
discontinuation occurred 4.8 days earlier and the median 
length of hospital stay was 4 days shorter (Table 1). • A retrospective chart review of 739 inpatient admissions 
to the LVH-Cedar Crest and LVH-Muhlenberg campuses 
from January 1st to March 31st 2018, who underwent 
PCT testing. 
• Exclusion criteria: patients <18 years of age, transferred 
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OBJECTIVE
Figure 1. Literature-based Procalcitonin (PCT) protocol for antibiotic 
administration1,2. *PCT results should not trump clinician judgment.                                                                       
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Table 1. Demographics and clinical data, stratified by concordant 
and discordant PCT starting and stopping antibiotic use.*†
Abbreviations: IQR, interquartile range; PCT, Procalcitonin; LVHN, Lehigh Valley Health Network. 
Assessment of provider concordance and discordance to PCT advice given a 24- hr. window for any PCT-driven antibiotic alterations, 
before and after PCT result reception. *n=52 cases of N/A start adherence, n=591 cases of N/A stop adherence.
† Concordant defined as: followed suggested PCT protocol. Discordant defined as: did not follow the suggested PCT protocol2.
• The purpose of this quality improvement project is 
to examine the real-world use of PCT at Lehigh 
Valley Health Network (LVHN) and assess the 
clinical impact of PCT-driven antibiotic usage.
Figure 4. Procalcitonin ordering by provider specialty. 
Figure 3. 30-day all-cause mortality and readmission rates (%) 
stratified by PCT-driven antibiotic adherence N=739. 
Figure 2. Median length of antibiotic therapy and hospital stay 
(days) stratified by PCT-driven antibiotic adherence N=739. 
• Discordant PCT test results and antibiotic usage occurred 
in 27.1% of cases during antibiotic initiation and in 26.4% 
of cases for applicable follow-up PCT testing.
• An increase in the days of antibiotic therapy, length of 
stay, 30-day mortality, and 30-day readmission rates were 
noted in discordant antibiotic start and stop cohorts, this 
warrants further analysis (Figure 2,3). 
• Increased education regarding appropriate Procalcitonin 
test usage and interpretation is needed at LVHN.
• Future Directions: explore effectiveness of properly used 
PCT tests to decrease hospital spending on excessive 
antibiotic-use and in turn, examine the impact on risks for 
antibiotic-resistance 
RESULTS
